



THERANOSTICS INSIGHTS

²²⁵Ac-RTX-2358



Radioisotope

Ac-225 Actinium-225
actinide metal
T_{1/2} : 9.9 days

Production

²²⁹Th/ ²²⁵Ac generators.
Other methods under development

Radiation

alpha particle (α)

Use

In clinical studies for relapsed and refractory soft tissue sarcoma with overexpression of Fibroblast Activation Protein (FAP).

Target/Mechanism

²²⁵Ac-RTX-2358 is the radio conjugate of a FAP inhibitor, designed to target specifically sarcoma cancer cells that express surface protein FAP. Once targeted, the ²²⁵Ac emits powerful short range alpha particles capable of causing double-strand DNA breakage leading to cancer cell death, while sparing the surrounding healthy tissues.

Insight

The ATLAS clinical trial (NCT07156565) it's a Phase 1/2 trial investigating safety, tolerability and anti-tumor activity of ²²⁵Ac-RTX-2358 in patients with relapsed or treatment-resistant soft tissue sarcoma. Diagnostic companion for patient's eligibility: ⁶⁴Cu-LNTH-1363S.

Phase 1 - dose escalation: aiming at identifying frequency and severity of adverse events and determine preliminary response. Designed as dose escalation 3+3 (7.5, 11.25 and 15 MBq) cohorts to be treated with single intravenous injection every 8 weeks, up to 6 cycles, over a period of 12 months.

Phase 2- dose expansion: evaluate the efficacy and safety in up to 50 patients at the Maximum Tolerated Dose (MTD) identified during phase 1.

